Peritonitis
Drug research and approvals for peritonitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 12 studies of peritonitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 12
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 12 recruiting on ClinicalTrials.gov ↗- Nitazoxanide in Spontaneous Bacterial PeritonitisNCT07808450 · Phase 1 / Phase 2 · Tanta University · starts Oct 25, 2026
- N-Acetylcysteine in the Management of Spontaneous Bacterial PeritonitisNCT07803952 · Phase 1 / Phase 2 · Tanta University · starts Oct 25, 2026
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNCT07923318 · Not applicable · Chonnam National University Hospital · starts Oct 4, 2026
- AIDE: Decision Support for Anastomosis or Colostomy in Emergency Surgery for Complicated Acute DiverticulitisNCT07651072 · Not reported · IRCCS San Raffaele Roma · starts May 15, 2026
- Benefit of Hypnosis on Smartphone for Acute Post-operative Pain (HYPNO-APP)NCT05854914 · Not applicable · Centre Hospitalier Universitaire de Nice · starts Jun 19, 2025
- Faecal Microbiota Transplantation for Liver CirrhosisNCT04932577 · Phase 2 / Phase 3 · University of Aarhus · starts Jul 1, 2021
- Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated DiverticulitisNCT04604730 · Not applicable · University Hospital, Rouen · starts Jun 11, 2021
- Vacuum Assisted Closure Versus On-demand Relaparotomy in Patients With Fecal or Diffuse PeritonitisNCT03932461 · Not applicable · Odense University Hospital · starts Jun 1, 2020
- Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial PeritonitisNCT04161768 · Phase 3 · Tanta University · starts Dec 1, 2018
- Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial PeritonitisNCT04168099 · Phase 3 · Tanta University · starts Dec 1, 2018
Drug Pipeline
6 approved, 10 in phase 3, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Ceftazidime, Amikacin, Clindamycin phosphate, Anidulafungin, Tazobactam, Piperacillin
- Norfloxacin
- Phase 3 Topoisomerase IV inhibitor
- Rifaximin
- Phase 3 Bacterial DNA-directed RNA polymerase inhibitor
- Ciprofloxacin
- Phase 3 Bacterial DNA gyrase inhibitor
- Cefotaxime
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Gemifloxacin
- Phase 3 DNA gyrase inhibitor
- Ceftriaxone
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Doripenem
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Nitazoxanide
- Phase 3 Pyruvate:ferredoxin oxidoreductase inhibitor
- Co-trimoxazole
- Phase 3 Bacterial dihydrofolate reductase inhibitor
- Itopride
- Phase 3 Dopamine D2 receptor antagonist
- Vancomycin
- Phase 1 Peptidoglycan inhibitor
How Its Trials Ended
187 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 28% met their primary endpoint, 5% missed it and 67% stopped early.
- Completed, result not reported7741%
- Status unknown4021%
- Ongoing3117%
- Stopped: other or unclear147%
- Met its primary endpoint116%
- Stopped: enrollment or feasibility74%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
- Stopped: safety11%
- Stopped: sponsor or business decision11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA